13F Holdings
中文EN

ALKS Alkermes plc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1520262 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY15.3%
TTM net income YoY-100.1%
TTM EPS YoY-100.5%
Revenue 3-yr CAGR3.3%
Net income 3-yr CAGR—

Margins

Gross margin82.9%
Operating margin3.7%
Net margin-0.0%
FCF margin13.0%
EBITDA margin8.3%

Returns

ROE-0.0%
ROA-0.0%
ROIC (approx.)1.7%
Asset turnover0.52x

Leverage & solvency

Liabilities / assets58.0%
Debt / equity0.80x
Current ratio2.42x
Interest coverage0.74x

Cash quality & payout

Operating cash flow / net income-692.27x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$1.48B$1.56B$1.66B$1.11B$1.17B
Cost of revenue$196.46M$245.33M$253.04M$218.07M$197.32M
Gross profit$1.28B$1.31B$1.41B$893.73M$976.43M
R&D expense$323.96M$245.33M$270.81M$272.70M$290.92M
SG&A expense$701.52M$645.24M$689.75M$590.75M$549.61M
Operating income$253.96M$420.64M$414.12M-$6.09M$97.75M
Interest expense$12.28M$22.58M$23.03M$13.04M$11.22M
Pretax income$291.45M$443.75M$421.52M-$31.13M$87.73M
Income tax$49.79M$71.61M-$97.64M$2.02M$11.33M
Net income$241.66M$367.07M$355.76M-$158.27M-$48.17M
EBITDA$281.12M$449.17M$489.05M$71.77M$176.40M
EPS (basic)1.472.222.14-0.97-0.30
EPS (diluted)1.432.172.10-0.97-0.29
Weighted avg. shares (diluted)168.74M169.20M169.73M163.74M164.75M
Balance sheet
Cash & equivalents$388.57M$291.15M$457.47M$292.47M$337.54M
Short-term investments$199.65M$460.52M$316.02M$315.99M$198.77M
Receivables$334.02M$384.53M$332.48M$287.97M$313.19M
Inventory$196.62M$182.89M$186.41M$181.42M$150.34M
Current assets$1.93B$1.42B$1.49B$1.13B$1.06B
PP&E, net$221.72M$227.56M$226.94M$222.92M$341.05M
Goodwill$83.03M$83.03M$83.03M$83.03M$92.87M
Intangibles$815,000$890,000$1.99M$37.68M$74.04M
Total assets$2.49B$2.06B$2.14B$1.96B$2.02B
Current liabilities$543.44M$465.20M$520.22M$497.74M$471.29M
Short-term debt$0—$3.00M$3.00M$3.00M
Long-term debt$0—$287.73M$290.27M$292.80M
Total debt$0—$290.73M$293.27M$295.80M
Total liabilities$667.70M$590.59M$933.54M$920.23M$911.90M
Shareholders' equity$1.82B$1.46B$1.20B$1.04B$1.11B
Net debt-$388.57M—-$166.74M$797,000-$41.74M
Shares outstanding165.61M162.18M166.98M164.38M161.94M
Cash flow statement
Operating cash flow$520.75M$439.12M$401.35M$21.04M$101.72M
Capital expenditure$40.42M$33.48M$48.05M$38.26M$28.02M
Free cash flow$480.33M$405.64M$353.31M-$17.21M$73.69M
Investing cash flow$295.50M-$111.31M$53.36M-$64.54M-$66.20M
Financing cash flow$12.38M-$494.14M-$289.71M-$1.57M$29.07M
Depreciation & amortization$27.16M$28.53M$74.93M$77.86M$78.65M
Stock-based compensation$98.72M$96.64M$100.91M$94.25M$87.62M
Share buybacks—$200.28M———

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.